The effects of transcutaneous auricular vagus nerve stimulation in epilepsy comorbid with migraine on the EEG power spectrum: a randomized controlled trial
Abstract
Background Migraine is a common comorbidity in patients with epilepsy, with a comorbidity rate ranging from 9.3 to 34.7%. Transcutaneous auricular vagus nerve stimulation (taVNS) is an emerging therapy used in both epilepsy and migraine treatment. However, there are currently no randomized controlled studies (RCTs) using taVNS for epilepsy complicated with migraine. Objective In this study, we evaluated the effect of taVNS as an adjuvant therapy on patients with comorbid epilepsy and migraine. Methods Forty comorbid patients (taVNS n = 20, tanVNS n = 20) were recruited and randomly grouped. The taVNS group received the true stimulus, whereas the tanVNS group received a pseudostimulus. Outcome assessment was performed at baseline and 24 weeks after initiation. We used t-test and non-parametric tests to analyse the data. Results The frequencies of migraine attacks and seizures significantly decreased in the taVNS group from baseline to 24 weeks (migraine attack frequency, p = 0.002; seizure frequency, p = 0.004), and so did in Self-Rating Anxiety Scale (SAS) score (p < 0.001) and Self-Rating Depression Scale (SDS) score (p < 0.001). The QOLIE-31 scores increased after 24 weeks of taVNS treatment (p = 0.028). Moreover, taVNS reduced the EEG power spectrum in four frequency bands at 16 electrode locations in comparison between groups (p < 0.05). Conclusion In comorbid patients in our groups, taVNS can decrease the frequency of seizures, improve mood and quality of life, and…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 20 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.